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Abstract
Background: Studies of cerebral ischemia and other neuroinflammatory states have demonstrated a strong
association between new vessel formation and microglial recruitment and activation, raising the possibility that
microglia may be involved in promoting angiogenesis. As endothelial cell proliferation is a fundamental early step
in angiogenesis, the aim of this study was to test this hypothesis by examining the influence of microglial secreted
factors on brain endothelial cell (BEC) proliferation using BrdU incorporation.
Methods: Primary cultures of mouse BEC, microglia and astrocytes were used in this study. Proliferation of BEC was
examined by BrdU incorporation. ELISA was used to quantify TNF and TGF-b1 levels within cell culture
supernatants.
Results: Microglia regulated BEC proliferation in a biphasic manner; microglia conditioned medium (MG-CM) from
resting microglia inhibited, while that from activated microglia promoted BEC proliferation. A screen of microglial
cytokines revealed that BEC proliferation was inhibited by TGF-b1, but promoted by TNF. ELISA showed that TNF
and TGF-b1 were both present in MG-CM, and that while TGF-b1 dominated in resting MG-CM, TNF levels were
massively increased in activated MG-CM, shifting the balance in favor of TNF. Antibody-blocking studies revealed
that the influence of MG-CM to inhibit or promote BEC proliferation was largely attributable to the cytokines TGF-
b1 and TNF, respectively.
Conclusion: This data suggests that microglial activation state might be an important determinant of cerebral
angiogenesis; inhibiting BEC proliferation and neovascularization in the normal central nervous system (CNS), but
stimulating the growth of new capillaries under neuroinflammatory conditions.
Background
Angiogenesis occurs in the central nervous system
(CNS) not just during development [1], but also in
pathological conditions, including cerebral ischemia [2],
neoplasia [3], and neuroinflammation [4,5]. An
improved understanding of the factors that control cere-
bral angiogenesis would be a big step forward in our
attempts to regulate angiogenesis for therapeutic means,
either to increase blood vessel growth during cerebral
ischemia, or to inhibit vessel growth during neoplasia.
A n g i o g e n e s i si sr e g u l a t e db yap l e t h o r ao ff a c t o r s ,
including growth factors [6], cytokines [7], and
extracellular matrix (ECM) molecules [8]. Within the
CNS, it has been established that hypoxia promotes
angiogenesis by at least two separate pathways. One
involves hypoxia inducible factor-1a (HIF-1a)-depen-
dent vascular endothelial growth factor (VEGF) release
[9], and the other, that involves a HIF-1a-independent
COX-2-dependent stimulation of PGE2, leading to
angiopoietin-2 release [10]. In addition to soluble fac-
tors, ECM proteins also provide important instructional
cues in angiogenesis [11], and recent work from our
laboratory showing that fibronectin is strongly induced
on angiogenic capillaries in the hypoxic CNS [12], as
well as on angiogenic vessels in the developing CNS
[13], suggests that this protein may also be important
for cerebral angiogenesis. * Correspondence: rmilner@scripps.edu
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occupy an angiostatic state, and have the impermeable,
tight-barrier characteristics of mature cerebral endothe-
lium [14]. During cerebral ischemia and other neuroin-
flammatory conditions, vessels in the adult CNS mount
an angiogenic response in which BEC proliferate to
form new capillary sprouts [15,16]. Interestingly, studies
of cerebral ischemic tissue have demonstrated a strong
association between new vessel formation and microglial
recruitment and activation [17,18], raising the possibility
that microglia, the principal immune effector cells in the
CNS, may actively promote angiogenesis. As endothelial
cell proliferation is a fundamental early step in the
angiogenic response, the aim of this study was to test
this hypothesis by examining the influence of microglial
secreted factors on BEC proliferation.
Materials and methods
Animals
The studies described have been reviewed and approved
by The Scripps Research Institute Institutional Animal
Care and Use Committee. All animals were maintained
under pathogen-free conditions in the closed breeding
colony of The Scripps Research Institute (TSRI).
Cell Culture
Pure cultures of mouse brain endothelial cells (BEC)
were prepared as previously described [19]. Briefly,
brains were removed from 8 week-old C57Bl/6 mice,
minced, dissociated for one hour in papain, centrifuged
through 22% BSA to remove myelin, and then endothe-
lial cells cultured in endothelial cell growth media
(ECGM) consisting of Hams F12, supplemented with
10% FBS, Heparin, ascorbic acid, L-glutamine, penicillin/
streptomycin (all from Sigma, St. Louis, MO) and
endothelial cell growth supplement (ECGS) (Upstate
Cell Signaling Solutions, Lake Placid, NY), on type I col-
lagen (Sigma)-coated 6-well plates. Puromycin (4 μg/ml,
Alexis GmbH, Grunberg, Germany) was included in cul-
ture media between days 1-3 to remove contaminating
cell types. Endothelial cell purity was >99% as deter-
mined by CD31 in flow cytometry. For all experiments,
BEC were used only for the first passage.
Mixed glial cultures were prepared from 0-2 day old
C57Bl/6 mouse pups, as previously described [19], and
maintained in poly-D-lysine coated T75 flasks in
DMEM containing 10% fetal bovine serum (FBS) (all
from Sigma). After 7-10 days, flasks were mechanically
shaken to yield microglia, which were plated into
uncoated 6 well plates. Microglial purity was >99% as
determined by Mac-1 in flow cytometry. Pure astrocyte
cultures were prepared as previously described [20], by
plating neurospheres into poly-D-lysine coated 6-well
plates and maintained in DMEM containing 10% FBS.
Astrocyte purity of these cultures was >99% as deter-
mined by GFAP immunocytochemistry.
Microglia-conditioned media (MG-CM)
Microglia were shaken off mixed glial cultures and pla-
ted in 6-well plates overnight. Media was then changed
to serum-free DMEM containing N1-supplement, L-glu-
tamine and penicillin/streptomycin (all from Sigma).
Microglia were left unstimulated or activated with 1 μg/
ml lipopolysaccharide (LPS, Sigma) to produce resting
and activated MG-CM respectively. After 3 days, media
was collected and filtered through a 0.22 μmf i l t e r
before use in BEC studies. Astrocyte conditioned media
(A-CM) was prepared in a similar manner.
Brain endothelial cell proliferation assay
Glass coverslips were coated with collagen I (10 μg/ml,
Sigma) for 2 hours, then washed, and BEC plated and
cultured until cells reached ~50% confluence. For inves-
tigation of the effect of MG-CM, BEC were cultured in
67% ECGM and 33% MG-CM. Control cultures were
maintained in 67% ECGM and 33% N1-supplemented
media. In the function-blocking experiments, the anti-
TNF and anti-TGF-b1 blocking antibodies and control
antibodies (R&D, Minneapolis, MN) were used at 2 μg/
ml. For the investigation of the influence of cytokines
on BEC proliferation, BEC were cultured in ECGM with
factors added across a concentration range, with the
maximum indicated: IFN-a (10
3 U/ml, PBL Biomedical
Labs), IFN-g (10 U/ml, R&D), IL-6 (20 ng/ml, R&D),
TNF (20 ng/ml, Genentech, San Francisco, CA), and
TGF-b1 (20 ng/ml, R&D). BEC were cultured for 16
hours in the presence of BrdU (Invitrogen, Carlsbad,
CA), then fixed in acid/alcohol and processed for BrdU
immunocytochemistry according to the manufacturer’s
instructions. BEC proliferation was assessed by quantify-
ing the number of BrdU-positive cells as a percentage of
the total number of cells (Hoechst staining), and the
results expressed as the mean ± SEM of four experi-
ments. Statistical significance was assessed by using Stu-
dent’s t test, in which p < 0.05 was defined as
statistically significant.
ELISA analysis of glial cytokine production
Concentrations of TNF and TGF-b1 in microglial and
astrocyte conditioned media were quantified by standard
ELISA techniques using the Duoset ELISA system (R&D)
according to the manufacturer’s instructions. Results
represent the mean ± SEM of 3 experiments, with each
sample examined in triplicate within each experiment.
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Microglial secreted factors regulate BEC proliferation in a
biphasic manner
Microglia were purified from mixed glial cultures of
postnatal mice, and grown in serum free media for 3
days, in the absence or presence of the activating agent
lipopolysaccharide (LPS), to produce microglia-condi-
tioned media (MG-CM) from resting (unstimulated) or
activated microglia, respectively. The influence of resting
or activated MG-CM on BEC proliferation was exam-
ined using BrdU incorporation. As shown in Figure 1,
MG-CM had a clear biphasic influence on BEC prolif-
eration rate. Compared to control conditions, resting
MG-CM strongly inhibited BEC proliferation (6.4 ±
2.0% vs. 20.6 ± 1.6%, p < 0.001), while activated MG-
CM had the opposite effect (30.1 ± 2.0% vs. 20.6 ± 1.6%,
p < 0.002). The influence of astrocyte-conditioned
media (A-CM) was also investigated. This revealed that
resting and activated A-CM both inhibited BEC prolif-
eration (resting A-CM 14.5 ± 1.8% vs. 20.6 ± 1.6%, p <
0.05, and activated A-CM 13.4 ± 1.0% vs. 20.6 ± 1.6%, p
< 0.01).
TNF and TGF-b1 have antagonistic effects on BEC
proliferation
Microglia produce a large number of cytokines, whose
production is heavily-dependent on the state of micro-
glial activation [21]. To identify which of these factors
might be responsible for the microglial influence on
BEC proliferation, we screened a panel of different cyto-
kines for their ability to regulate BEC proliferation. This
showed that TNF and TGF-b1 had the strongest, though
opposing influences on BEC proliferation (Figure 2).
TNF promoted BEC proliferation in a dose-dependent
manner, which plateaued at a concentration of 10 ng/
ml. Compared to control conditions (21.3 ± 1.4%), 10
ng/ml TNF increased the rate of BEC proliferation to
32.6 ± 4.5% (p < 0.01). In contrast, TGF-b1 reduced the
rate of BEC proliferation, an effect which plateaued at a
concentration of 10 ng/ml. Compared to control condi-
tions, this concentration of TGF-b1 reduced BEC prolif-
eration from 20.6 ± 1.9% to 13.8 ± 2.1% (p < 0.05). IFN-
a,I F N - g and IL-6 had no significant effect on BEC pro-
liferation at any concentration tested.
Microglia secrete TNF and TGF-b1, with the balance
determined by microglial activation state
We have demonstrated that BEC proliferation rate is
regulated by MG-CM in a biphasic manner; inhibited by
resting MG-CM, and promoted by activated MG-CM.
Furthermore, we have shown that BEC proliferation is
inhibited by TGF-b1, but promoted by TNF. While it is
known from previous studies that microglia can produce
these two cytokines [22,23], we next used ELISA to
investigate in our own cultures, whether MG-CM con-
tained TNF or TGF-b1, and how this expression is regu-
lated by LPS. As shown in Figure 3A, TNF was present
in resting MG-CM (27.7 ± 8.6 pg/ml), but strongly
increased (50-fold) in activated MG-CM (1381.2 ± 82.7
pg/ml). In contrast, TGF-b1 levels were not significantly
different in resting (196.5 ± 42.3 pg/ml) or activated
Figure 1 Regulation of BEC proliferation by microglial-
conditioned medium. A. Dual immunocytochemistry for BrdU and
Hoechst demonstrated that BEC proliferation was inhibited by
conditioned media from resting microglia (MG-CM (rest)), but
promoted by conditioned media from activated microglia (MG-CM
(activ)). Scale bar = 100 μm. B. Quantification of BEC proliferation in
response to microglia-conditioned media (MG-CM) and astrocyte-
conditioned media (A-CM). BEC proliferation was examined over 16
hours, and expressed as the percentage of BEC that incorporated
BrdU; all points represent the mean ± SEM of 4 experiments. MG-
CM from resting or activated microglia, inhibited or promoted BEC
proliferation, respectively. A-CM from resting and activated
astrocytes both inhibited BEC proliferation. p < 0.05.
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tained no TNF, either before or after activation (Figure
3A). A-CM did contain TGF-b1, though this expression
was not regulated by LPS treatment, and was at lower
levels than MG-CM (39.2 ± 23.6 pg/ml and 75 ± 20.5
pg/ml in resting and activated A-CM, respectively).
Thus, microglial activation switches the TNF/TGF-b1
balance heavily in favor of TNF.
Microglial supernatants regulate BEC proliferation via TNF
and TGF-b1
To address whether the influence of MG-CM on BEC
proliferation is mediated by TNF or TGF-b1, we exam-
ined the influence of resting or activated MG-CM on
BEC proliferation in the presence of function-blocking
antibodies directed against TNF or TGF-b1. As shown
in Figure 4A, compared to control conditions (20.9 ±
1.6%), resting MG-CM (Con IgG) significantly inhibited
BEC proliferation (7.2 ± 2.0%, p < 0.005). This effect
was significantly released by the anti-TGF-b1a n t i b o d y
(12.5 ± 1.0%, p < 0.01). In contrast, compared to control
conditions (19.7 ± 1.4%), activated MG-CM (Con IgG)
significantly increased BEC proliferation (29.2 ± 1.7%, p
< 0.01; Figure 4B), and this effect was significantly inhib-
ited by the anti-TNF blocking antibody (18.9 ± 1.7%, p <
0.01). This data strongly suggests that TGF-b1i si np a r t
responsible for the negative influence of resting MG-
CM on BEC proliferation, and conversely, implicates
TNF as a major factor responsible for the positive effect
of activated MG-CM on BEC proliferation.
Discussion
Cerebral angiogenesis occurs in the adult CNS in a
number of conditions, including cerebral ischemia [2],
neoplasia [3], and the neuroinflammatory conditions
multiple sclerosis [5], and Alzheimer’s disease [4]. In
these conditions, angiogenesis is often associated with
microglial accumulation and activation [17,18], raising
the possibility that activated microglia may promote
angiogenic events. In the current study, we directly
examined this question in vitro, by exposing BEC to
microglia-conditioned media. This revealed that micro-
glia regulate BEC proliferation in a biphasic manner.
Soluble factors from resting microglia inhibit, while
those from activated microglia promote BEC prolifera-
tion, and these effects are largely attributable to the
microglial cytokines TGF-b1a n dT N F ,r e s p e c t i v e l y .
This data suggests that in vivo, microglial activation
state might be an important determinant of the earliest
stage of cerebral angiogenesis, namely endothelial cell
Figure 2 Quantification of BEC proliferation in response to
cytokines. BEC proliferation was examined over 16 hours in the
presence of different concentrations of the cytokines, IFN-a (A), IFN-
g (B), IL-6 (C), TGF-b1 (D), or TNF (E). BEC proliferation is expressed
as the percentage of BEC that incorporated BrdU; all points
represent the mean ± SEM of 4 experiments. Note that BEC
proliferation was significantly stimulated by TNF, and inhibited by
TGF-b1. p < 0.05.
Figure 3 ELISA quantification of TNF (A) and TGF-b1( B )
production by microglia or astrocytes, under resting or LPS-
activated conditions. All points are expressed in pg/ml
concentration of cytokine and represent the mean ± SEM of 4
experiments. Microglial activation resulted in a massive increase in
TNF production (50-fold), while astrocytes produced no TNF, even
after LPS stimulation. Activation had no significant influence on
TGF-b1 production by either cell type.
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CNS, tonic levels of TGF-b1 inhibit BEC proliferation,
but that during cerebral ischemia or other neuroinflam-
matory processes, activated microglia ramp up TNF pro-
duction, which promotes BEC proliferation.
Microglial activation and angiogenesis
Microglia, as the primary immune effector cells in the
CNS, play important roles in the surveillance and
response to pathological insults. As the gatekeeper of
the BBB, microglia are well positioned to mount a rapid
aggressive response to noxious stimuli that enter the
CNS. Under normal conditions, microglia occupy a rest-
ing “on surveillance” phenotype, but after stimulation,
switch to an activated highly migratory, mitogenic phe-
notype, with upregulated production of inflammatory
cytokines such as TNF and IFN-g [21,24]. Within days
of an ischemic insult, angiogenic remodeling can be
o b s e r v e da tt h ei s c h e m i cp e n u mbra [15,16], and inter-
estingly, angiogenic vessels are often surrounded by
inflammatory microglia and macrophages [17,18], sug-
gesting that activated microglia and/or macrophages
may be instrumental in promoting the angiogenic
response to cerebral ischemia. While this idea has not
yet been directly tested in the ischemic CNS, traumatic
CNS injury leads to activation of microglia and macro-
phages, and drugs that block activation and proliferation
of these cells, also inhibit neovascularization [25]. In
addition, studies from outside the CNS support the con-
cept that activated cells of the macrophage lineage
directly promote angiogenic events. In tumor models,
depletion of monocytes, the blood precursors of tissue
macrophages, leads to marked reduction in tumor-asso-
ciated angiogenesis [26], and conversely, addition of tis-
sue macrophages strongly promotes neovascularization
in corneal and rabbit ear chamber models [27,28]. Con-
sistent with this, and in agreement with our own find-
ing, conditioned media taken from activated
macrophages directly promotes endothelial cell prolif-
eration in vitro [29].
The influence of TNF and TGF-b1 on angiogenic events
Our studies suggest that the positive and negative influ-
ences of microglia on BEC proliferation is mediated, at
least in part, by the antagonistic cytokines TNF and
TGF-b1, respectively. The influence of these cytokines
on angiogenic events is still a matter of debate, with dif-
ferent studies demonstrating either pro- or anti-angio-
genic effects, depending on the source of endothelial
cells and the concentration of cytokine employed. TNF
has been shown to both promote [30-32] and inhibit
[33] angiogenic events, with one report demonstrating a
negative effect of TNF on endothelial cell proliferation
in vitro, but a stimulation of neovascularization in vivo
[34], while another showed both positive and negative
effects on endothelial cell proliferation, depending on
the cellular source and cytokine combinations [35].
Similar apparently conflicting data have also been
described for TGF-b1 [7,36]. In an attempt to reconcile
these data, it has been suggested that the effects of these
factors may have biphasic effects on angiogenesis,
depending on cytokine concentration [36]. To directly
investigate this possibility, we examined BEC prolifera-
tion across a wide range of cytokine concentrations, but
in each case, this demonstrated a clear dose-response
effect in one direction only, namely TNF promoting and
TGF-b1 inhibiting BEC proliferation. Significantly,
recent data has shown that the biphasic effect of TNF
on endothelial cells can be explained by antagonistic
functions of the TNF receptors TNFR1 and TNFR2,
with TNFR2 stimulating endothelial cell survival, migra-
tion, and angiogenesis, while TNFR1 inhibits these func-
tions [37,38]. In the current study, close examination of
the TGF-b1 concentrations that mediated an inhibitory
effect on BEC proliferation revealed an apparent differ-
ence in the potency of the endogenous form (present in
resting MG-CM; 0.2 ng/ml) when compared with the
pure recombinant form (5 ng/ml). Two reasons may
Figure 4 Function-blocking experiments to examine the role of
TNF and TGF-b1 in mediating the effects of MG-CM. BEC
proliferation is expressed as the percentage of BEC that
incorporated BrdU; all points represent the mean ± SEM of 4
experiments. Note that the inhibitory influence of resting MG-CM
was partially relieved by TGF-b1 antibodies (A) and conversely, the
mitogenic influence of activated MG-CM was abrogated by anti-TNF
antibodies (B). p < 0.05.
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binant TGF-b1 did not reach statistical significance until
a concentration of 5 ng/ml, it did have an inhibitory
trend at lower concentrations (0.5-1 ng/ml). Second and
perhaps more important, in this study we used the
human recombinant form of TGF-b1 ,a n di ti se n t i r e l y
plausible that the biological activity of this form on
mouse BEC may not be as high as the endogenous mur-
ine form.
In summary, our data provides evidence that micro-
glia, the principal immune effector cells in the CNS, can
regulate BEC proliferation in a biphasic manner by
altering the balance of TNF and TGF-b1. As BEC prolif-
eration is an early stage of the angiogenic process, and
new vessel formation leads to increased cerebral blood
flow [39] and clinical outcome [40,41], our findings sug-
gest that a controlled level of microglial activation and
TNF release might prove beneficial in the treatment of
stroke patients by promoting BEC proliferation and sub-
sequent neovascularization. In light of the recent finding
that microglia protect neurons from ischemia via a
TNF-mediated mechanism [42], this approach has the
potential to stimulate a positive outcome via two sepa-
rate mechanisms.
Conclusions
Our data demonstrate that microglia regulate BEC pro-
liferation in a biphasic manner; microglia conditioned
medium (MG-CM) from resting microglia inhibit, while
that from activated microglia promote BEC proliferation.
BEC proliferation was also inhibited by TGF-b1, but
promoted by TNF. ELISA showed that TNF and TGF-
b1 are both present in MG-CM, and that while TGF-b1
dominated in resting MG-CM, TNF levels were mas-
sively increased in activated MG-CM, shifting the bal-
ance in favor of TNF. Antibody-blocking studies
revealed that the influence of MG-CM to inhibit or pro-
mote BEC proliferation was largely attributable to the
cytokines TGF-b1 and TNF, respectively. Taken
together, this data suggests that microglial activation
state might be an important determinant of BEC prolif-
eration, an early event in cerebral angiogenesis.
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